Cadrenal Therapeutics正在开发针对高风险患者（包括肾病或高强度中歇）的新型抗凝药物，其主导药物特卡法林及已收购资产针对未被满足的医疗需求。 Cadrenal Therapeutics is developing new anticoagulants for high-risk patients, including those with kidney disease or HIT, with its lead drug tecarfarin and acquired assets targeting unmet medical needs.

Cadrenal Therapeutics（纳斯达克代码：CVKD）通过针对常被排除在主流治疗之外的高风险患者，包括终末期肾病、肾功能不稳定或肝素诱导血小板减少症（HIT）患者，推动一种新的抗凝方法。 Cadrenal Therapeutics (NASDAQ:CVKD) is advancing a new approach to anticoagulation by targeting high-risk patients often excluded from mainstream treatments, including those with end-stage kidney disease, unstable renal function, or heparin-induced thrombocytopenia (HIT). 其主要药物Tecarfarin是下一代维生素K敌国,旨在提供更加稳定和可预测的抗凝固药,减少肾依赖性和可逆性。 Its lead drug, tecarfarin, a next-generation vitamin K antagonist, aims to provide more stable and predictable anticoagulation with reduced kidney dependence and reversibility. 该公司扩大了平台,购置了一个用于更安全的急性护理使用的因数XIa抑制剂组合和VLX-1005。 VLX-1005是HIT第二阶段的一级12LOX抑制剂,它拥有孤儿药品和快车道标签。 The company expanded its platform by acquiring a Factor XIa inhibitor portfolio for safer acute care use and VLX-1005, a first-in-class 12-LOX inhibitor in Phase 2 for HIT, which holds Orphan Drug and Fast Track designations. 这些资产构成三个不同的科学支柱,侧重于慢性和急性抗凝聚方面未满足的需要。 These assets form three distinct scientific pillars focused on unmet needs in chronic and acute anticoagulation.